6,7-dimethoxy-2-thiophen-3-yl-quinoxaline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6,7-dimethoxy-2-thiophen-3-yl-quinoxaline
• 英文别名: 2-(thien-3-yl)-6,7-dimethoxyquinoxaline；6,7-dimethoxy-2-thiophen-3-ylquinoxaline
• 化学式: C₁₄H₁₂N₂O₂S
• 分子量: 272.327
• InChiKey: AGCKSNJFAADRHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  72.5
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
  申请人：Nesbit Mark

  公开号：US20070197538A1

  公开（公告）日：2007-08-23

  This invention is directed to potent inhibitors of protein tyrosine kinase alone or in synergistic combination with antiangiogenic or chemotherapeutic agents for the abrogation of mature vasculature within chemotherapeutic refractory tumors, pharmaceutical compositions comprising these compounds, and to the use of these compounds for treating a patient suffering from or subject to disorders/conditions involving cell proliferation, and particularly treatment of brain cancer, ovarian cancer, pancreatic cancer prostate cancer, and human leukemias, such as CML, AML or ALL.

  本发明涉及针对蛋白酪氨酸激酶的强效抑制剂，单独或与抗血管生成或化疗药物协同使用，用于消除化疗难治性肿瘤内的成熟血管，以及包含这些化合物的制药组合物，并且用于治疗患有或患有涉及细胞增殖的疾病/病症的患者，特别是治疗脑癌、卵巢癌、胰腺癌、前列腺癌和人类白血病，如慢性髓细胞白血病、急性髓细胞白血病或急性淋巴细胞白血病。
• Combination for the treatment of endothelial damage
  申请人：——

  公开号：US20030099687A1

  公开（公告）日：2003-05-29

  The invention relates to a combination of (a) an inhibitor of platelet-derived growth factor (PDGF) activity and (b) a vector for vascular endothelial growth factor (VEGF-, especially VEGF-C) gene transfer, a pharmaceutical preparation comprising (a) and (b) in combination together with a pharmaceutically acceptable carrier material; a product comprising (a) and (b) as defined above and optionally a pharmaceutically acceptable carrier material, for simultaneous, chronologically staggered or separate use; a method of administering or the use of said combination or product for the treatment of endothelial damage; and/or to the use of (a) and (b) for the manufacture of said pharmaceutical preparation or product for the treatment of endothelial damage.

  本发明涉及一种(a)血小板衍生生长因子(PDGF)活性抑制剂和(b)血管内皮生长因子(VEGF-，特别是VEGF-C)基因转移载体的组合物，一种药物制剂，包括(a)和(b)的组合物以及一种药学上可接受的载体材料；由上述(a)和(b)以及可选的药学上可接受的载体材料组成的产品，可同时使用、按时间顺序交错使用或单独使用；治疗内皮损伤的给药方法或使用所述组合或产品的方法；和/或使用(a)和(b)制造治疗内皮损伤的所述药物制剂或产品。
• Combinations of (a) an atp-competitive inhibitor of c-acl kinase activity with (b) two or more other antineoplastic agents
  申请人：Avramis Alexander Ioannis

  公开号：US20050113384A1

  公开（公告）日：2005-05-26

  The invention relates to combinations of (a) an ATP-competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease.

  本发明涉及(a)c-abl激酶活性的ATP竞争性抑制剂与(b)两种或两种以上其他抗肿瘤药物的复方制剂，可同时、分别或依次使用，特别是用于延缓增殖性疾病的进展或治疗。
• EP0584222A4
  申请人：——

  公开号：EP0584222A4

  公开（公告）日：1994-07-06
• BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE
  申请人：RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC.

  公开号：EP0584222B1

  公开（公告）日：1997-10-08